LUGENE ANALYTICS
DEAD

Serial Number

90340575

Owner

Ampel, LLC

Attorney

Patrick C. Asplin

First Use Date

Oct 29, 2018

Filing Date

Nov 24, 2020

Add to watchlist:

No watchlists yet
View on USPTO

LUGENE ANALYTICS Trademark

Serial Number: 90340575

LUGENE ANALYTICS is a trademark filed by Ampel, LLC on November 24, 2020. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Ampel, LLC (46 trademarks)

250 West Main St., Ste. 300
Charlottesville, VA 22902

Entity Type: 16

Trademark Details

Filing Date

November 24, 2020

Registration Date

Not Registered

First Use Anywhere

October 29, 2018

First Use in Commerce

October 29, 2018

Goods & Services

Medical information services, namely, providing medical information relating to the suitability of patients for clinical trials based on their genetic profiles and gene expression; providing medical information relating to the best drug options for individuals with autoimmune diseases, cardiovascular disease, inflammatory diseases, neurological diseases, infectious diseases and oncological diseases based on their genetic profile and gene expression

Providing temporary use of non-downloadable computer software applications for grouping and categorizing human genes according to their biological function, analyzing the role of genes in promoting or inhibiting disease activity associated with autoimmune diseases, cardiovascular disease, inflammatory diseases, neurological diseases, infectious diseases and oncological diseases and scoring such genes based on their role in promoting or inhibiting such disease activity, identifying blood and non-blood cells within the gene sequences contained in human tissues and organs, and analyzing genes and genetic profiles to assess disease activity in patients suffering from autoimmune diseases, cardiovascular disease, inflammatory diseases, neurological diseases, infectious diseases and oncological diseases, and assessing the efficacy of pharmaceuticals, drug therapies and treatments to treat such diseases

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 23, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jun 23, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 23, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 10, 2021 GNRN
NON-FINAL ACTION E-MAILED
Dec 10, 2021 GNRT
NON-FINAL ACTION WRITTEN
Dec 10, 2021 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 12, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 11, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 11, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 11, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 11, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 11, 2021 CNRT
ASSIGNED TO EXAMINER
May 7, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 30, 2021 NWOS
NEW APPLICATION ENTERED
Nov 27, 2020 NWAP